AdvisorShares Dorsey Wright FSM All Cap World ETF (DWAW)
Filed: 21 Nov 24, 5:23pm
ADVISORSHARES PSYCHEDELICS ETF
Schedule of Investments
September 30, 2024 (Unaudited)
| Investments | Shares | Value | ||||||
| COMMON STOCKS – 95.5% | ||||||||
| Biotechnology – 74.9% | ||||||||
| ATAI Life Sciences NV (Germany)(a)(b) | 167,831 | $ | 194,684 | |||||
| Bright Minds Biosciences, Inc. (Canada)(b) | 182,420 | 218,904 | ||||||
| Clearmind Medicine, Inc. (Canada)†(b) | 170,641 | 208,182 | ||||||
| Cybin, Inc. (Canada)(b) | 49,084 | 436,357 | ||||||
| Enveric Biosciences, Inc.(b) | 367,047 | 173,980 | ||||||
| GH Research PLC (Ireland)(b) | 31,205 | 208,761 | ||||||
| Incannex Healthcare, Inc.(a)(b) | 126,990 | 252,710 | ||||||
| Intra-Cellular Therapies, Inc.(b) | 2,805 | 205,242 | ||||||
| Mind Medicine MindMed, Inc.(b) | 109,166 | 621,154 | ||||||
| NRX Pharmaceuticals, Inc.(b) | 130,085 | 219,844 | ||||||
| PsyBio Therapeutics Corp.(b) | 2,994,817 | 3 | ||||||
| Psyence Biomedical Ltd. (Canada)†(b) | 1,232,376 | 123,238 | ||||||
| Sage Therapeutics, Inc.(b) | 23,330 | 168,443 | ||||||
| Seelos Therapeutics, Inc.(b) | 18,113 | 68,014 | ||||||
| Vistagen Therapeutics, Inc.(b) | 67,780 | 204,018 | ||||||
| Total Biotechnology | 3,303,534 | |||||||
| Healthcare - Services – 1.7% | ||||||||
| Field Trip Health & Wellness Ltd. (Canada)(b)(c) | 1,058,415 | 0 | ||||||
| Greenbrook TMS, Inc. (Canada)(b) | 1,145,349 | 9,163 | ||||||
| Lucy Scientific Discovery, Inc. (Canada)†(b) | 128,160 | 1,282 | ||||||
| Numinus Wellness, Inc. (Canada)(b) | 2,673,274 | 63,089 | ||||||
| Total Healthcare - Services | 73,534 | |||||||
| Pharmaceuticals – 18.9% | ||||||||
| Alkermes PLC(b) | 8,290 | 232,037 | ||||||
| Compass Pathways PLC (United Kingdom)(a)(b)(d) | 43,882 | 276,456 | ||||||
| FSD Pharma, Inc. (Canada)(b)(c) | 263,236 | 0 | ||||||
| Quantum BioPharma Ltd. (Canada)(b) | 26,233 | 104,932 | ||||||
| Relmada Therapeutics, Inc.(b) | 68,528 | 222,031 | ||||||
| Total Pharmaceuticals | 835,456 | |||||||
| Total Common Stocks (Cost $9,940,342) | 4,212,524 | |||||||
| MONEY MARKET FUNDS – 13.8% | ||||||||
| BlackRock Liquidity Funds Treasury Trust Fund Portfolio, Institutional Class, 4.89%(e) | 260,109 | 260,109 | ||||||
| Dreyfus Institutional Preferred Government Money Market Fund, Institutional Class, 4.88%(e)(f) | 347,392 | 347,392 | ||||||
| Total Money Market Funds (Cost $607,501) | 607,501 | |||||||
| Total Investments – 109.3% (Cost $10,547,843) | 4,820,025 | |||||||
| Liabilities in Excess of Other Assets – (9.3%) | (412,384 | ) | ||||||
| Net Assets – 100.0% | $ | 4,407,641 | ||||||
PLC - Public Limited Company
| † | Affiliated Company. |
| (a) | All or a portion of security is on loan. The aggregate market value of the securities on loan is $323,723; the aggregate market value of the collateral held by the fund is $347,392. |
| (b) | Non-income producing security. |
| (c) | Fair valued using significant unobservable inputs. |
| (d) | American Depositary Receipt. |
| (e) | Rate shown reflects the 7-day yield as of September 30, 2024. |
| (f) | Collateral received from brokers for securities lending was invested in these short-term investments. |
ADVISORSHARES PSYCHEDELICS ETF
Schedule of Investments (continued)
September 30, 2024 (Unaudited)
For information on the Fund’s policies regarding the valuation of investments and other significant accounting policies, please refer to the Fund’s most recent semi-annual or annual financial statements.
Fair Value Measurements
The following is a summary of the inputs used, as of September 30, 2024, in valuing the Fund’s assets and liabilities carried at fair value. These inputs are summarized in three broad levels. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds and credit risk). Level 3 includes significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments). The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities.
| Assets | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
| Common Stocks | $ | 4,212,524 | $ | – | $ | 0 | * | $ | 4,212,524 | |||||||
| Money Market Funds | 607,501 | – | – | 607,501 | ||||||||||||
| Total | $ | 4,820,025 | $ | – | $ | 0 | * | $ | 4,820,025 | |||||||
| * | Less than $1. |
SUMMARY OF SCHEDULE OF INVESTMENTS
| % of | ||||
| Net Assets | ||||
| Biotechnology | 74.9 | % | ||
| Healthcare - Services | 1.7 | |||
| Pharmaceuticals | 18.9 | |||
| Money Market Funds | 13.8 | |||
| Total Investments | 109.3 | |||
| Liabilities in Excess of Other Assets | (9.3 | ) | ||
| Net Assets | 100.0 | % | ||
Affiliated holdings are investments or an affiliate of the Trust. Transactions with affiliated companies during the period ended September 30, 2024 were as follows:
| Affiliated Holding Name | Value at 6/30/2024 | Purchases/ Additions | Sales/ Reductions | Realized Gain (Loss) | Change in Unrealized Gain (Loss) | Number of Shares at 9/30/2024 | Value at 9/30/2024 | Dividend Income | ||||||||||||||||||||||||
| Clearmind Medicine, Inc. | $ | 216,117 | $ | 67,356 | $ | – | $ | – | $ | (75,291 | ) | 170,641 | $ | 208,182 | $ | – | ||||||||||||||||
| Lucy Scientific Discovery, Inc. | 65,862 | – | – | – | (64,580 | ) | 128,160 | 1,282 | – | |||||||||||||||||||||||
| Psyence Biomedical Ltd. | 138,913 | 198,001 | – | – | (213,676 | ) | 1,232,376 | 123,238 | – | |||||||||||||||||||||||
| Total | $ | 420,892 | $ | 265,357 | $ | – | $ | – | $ | (353,547 | ) | 1,531,177 | $ | 332,702 | $ | – | ||||||||||||||||